US-based biopharma, Actuate Therapeutics’s elraglusib reduced the risk of death by 37% in a Phase I/II metastatic pancreatic cancer trial. The randomised Phase I/II trial (NCT03678883) evaluated ...

Actuate Therapeutics (NASDAQ: ACTU), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, recently announced the ...

CHICAGO and FORT WORTH, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...

With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...

Actuate Therapeutics (ACTU) announced that the European Medicines Agency, EMA, has granted Orphan Medicinal Product Designation, OMPD, to elraglusib, a novel GSK-3beta inhibitor, for the treatment ...

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for ...

Meet security experts, leaders, managers & thought leaders from Actuate. Read detailed professional profiles on these movers & shakers. Check out their insights and articles on important security ...

CHICAGO and FORT WORTH, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused ...

CHICAGO and FORT WORTH, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...